Sebastián Olga Gavín, Fernández Macarena Izuzquiza, Fernández Raquel Martínez, Bernal Luis Palomera
Servicio de Hematología y Hemoterapia, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.
Future Cardiol. 2019 Sep;15(5):347-353. doi: 10.2217/fca-2018-0086. Epub 2019 Aug 30.
To determine drug persistence and rates of events among patients treated with rivaroxaban in a hematology unit. Retrospective study of patients that started treatment with rivaroxaban, in the hematology unit of a tertiary hospital. A total of 161 patients were included, of whom 83.9% had atrial fibrillation and 11.2% venous thromboembolism, and 76.4% of patients were taking rivaroxaban 20 mg, 22.4% 15 mg and 1.2% 10 mg. After a follow-up of 1.8 ± 1.1 years, only four patients (2.5%) discontinued treatment. Rates of thromboembolic events, major bleeding/clinically relevant nonmajor bleeding and intracranial hemorrhage were 1.1, 2.8, 0.3 events per 100 patient-years, respectively. In patients attended in a hematology unit, medication persistence was high, and the incidence of outcomes low.
为确定在血液科接受利伐沙班治疗的患者的药物持续性及事件发生率。对一家三级医院血液科开始接受利伐沙班治疗的患者进行回顾性研究。共纳入161例患者，其中83.9%患有心房颤动，11.2%患有静脉血栓栓塞，76.4%的患者服用20mg利伐沙班，22.4%服用15mg，1.2%服用10mg。经过1.8±1.1年的随访，仅有4例患者（2.5%）停药。血栓栓塞事件、大出血/临床相关非大出血及颅内出血的发生率分别为每100患者年1.1次、2.8次、0.3次。在血液科就诊的患者中，药物持续性较高，不良事件发生率较低。
